- Byers KE, Durbin LJ, Simonton BM, et al. Disinfection of hospital rooms contaminated with
vancomycin-resistantEnterococcu faecium. Infect Control Hosp Epidemiol 1998;19(4):261–264 - Hota B, Blom DW, Lyle EA, et al. Interventional evaluation of environmental contamination by
vancomycin-resistant enterococci: failure of personnel, product, or procedure? J Hosp Infect 2009;
71(2):123–131. - Carmeli Y, Venkataraman L, DeGirolami PC, et al. Stool colonization of healthcare workers with
selected resistant bacteria. Infect Control Hosp Epidemiol 1998;19(1):38–40. - Fridkin SK, Lawton R, Edwards JR, et al. Monitoring antimicrobial use and resistance: comparison
with a national benchmark on reducing vancomycin use and vancomycin resistant enterococci.
Emerg Infect Dis 2002;8(7):702–707. - Quale J, Landman D, Saurina G, et al. Manipulation of a hospital antimicrobial formulary to control
an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23(11):1020–1025. - May AK, Melton SM, McGwin G, et al. Reduction of vancomycin-resistant enterococcal infections by
limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. Shock
2000;14(3):259–264. - Chavers LS, Moser SA, Funkhouser E, et al. Association between antecedent intravenous
antimicrobial exposure and isolation of vancomycin-resistant enterococci. Microb Drug Resist
2003;9(suppl 1):S69–S77. - Stiefel U, Paterson DL, Pultz NJ, et al. Effect of the increasing use of piperacillin/tazobactam on the
incidence of vancomycin-resistant enterococci in four academic medical centers. Infect Control Hosp
Epidemiol 2004;25(5):380–383. - Winston LG, Charlebois ED, Pang S, et al. Impact of a formulary switch from ticarcillin-clavulanate
to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci. Am J Infect
Control 2004;32(8):462–469. - Paterson DL, Muto CA, Ndirangu M, et al. Acquisition of rectal colonization by vancomycin-
resistantEnterococcusamong intensive care unit patients treated with piperacillin-tazobactam versus
those receiving cefepime-containing antibiotic regimens. Antimicrob Agents Chemother 2008;
52(2):465–469. - Montecalvo MA, Jarvis WR, Uman J, et al. Costs and savings associated with infection control
measures that reduced transmission of vancomycin-resistant enterococci in an endemic setting.
Infect Control Hosp Epidemiol 2001;22(7):437–442. - Muto CA, Giannetta ET, Durbin LJ, et al. Cost-effectiveness of perirectal surveillance cultures for
controlling vancomycin-resistantEnterococcus. Infect Control Hosp Epidemiol 2002;23(8):429–435. - Carmeli Y, Eliopoulos G, Mozaffari E, et al. Health and economic outcomes of vancomycin-resistant
enterococci. Arch Intern Med 2002;162(19):2223–2228. - Puzniak LA, Gillespie KN, Leet T, et al. A cost-benefit analysis of gown use in controlling
vancomycin-resistant Enterococcus transmission: is it worth the price? Infect Control Hosp
Epidemiol 2004;25(5):418–424.
MRSA/VRE Colonization and Infection in the Critical Care Unit 127